Table 1 Baseline characteristics and qualifying genomics by group.
Characteristic | Group 1 (n = 16) | Group 2 (n = 32) | ||
|---|---|---|---|---|
No. | % | No. | % | |
Median age, years (range) | 56 (23–71) | 54 (20–76) | ||
Male sex | 8 | 50% | 13 | 41% |
ECOG status | ||||
0 | 15 | 94% | 24 | 75% |
1 | 1 | 6% | 8 | 25% |
Lines of prior systemic treatment | ||||
Median line (range) | 1.5 (1–3) | 2 (0–5) | ||
Prior lines <2 | 8 | 50% | 9 | 28% |
Cancer type | ||||
Bone and soft tissue sarcomas | 4 | 25% | 8 | 25% |
Alveolar soft part sarcoma | 1 | 3% | ||
Chondrosarcoma | 2 | 6% | ||
Ewing’s sarcoma | 1 | 3% | ||
Leiomyosarcoma | 2 | 13% | 2 | 6% |
Liposarcoma | 2 | 6% | ||
Osteosarcoma | 1 | 6% | 1 | 3% |
PEComa | 1 | 6% | ||
Carcinomas | 12 | 75% | 24 | 75% |
Anal, SCC | 1 | 3% | ||
Breast, IDC | 2 | 6% | ||
Cervix adenocarcinoma | 1 | 6% | ||
Cholangiocarcinoma, gallbladder adenocarcinoma | 2 | 13% | ||
Colorectal adenocarcinoma | 1 | 6% | 3 | 9% |
CUP | 1 | 3% | ||
Endometrial adenocarcinoma | 2 | 6% | ||
Ethmoid sinus adenocarcinoma | 1 | 6% | ||
Gastric adenocarcinoma | 1 | 6% | 1 | 3% |
Glioma | 1 | 6% | 2 | 6% |
Medulloblastoma | 1 | 3% | ||
Meningioma, anaplastic | 1 | 3% | ||
Neuroendocrine carcinoma | 1 | 3% | ||
Ovarian adenocarcinoma | 1 | 3% | ||
Ovarian, sex cord-stromal tumour | 1 | 3% | ||
Pancreas adenocarcinoma | 4 | 25% | 2 | 6% |
Small intestine adenocarcinoma | 1 | 6% | 1 | 3% |
Thyroid carcinoma, papillary | 1 | 3% | ||
Uveal melanoma | 2 | 6% | ||
Qualifying genomic biomarker | ||||
BRCA1 | 4^ | 25% | ||
BRCA2 | 12 | 75% | ||
ATM | 10# | 31% | ||
ATR | 1 | 3% | ||
BAP1 | 2 | 6% | ||
BARD1 | 1* | 3% | ||
BRIP1 | 2$ | 6% | ||
CDK12 | 3+* | 3% | ||
CHEK1 | 1 | 3% | ||
CHEK2 | 3 | 9% | ||
FANCA | 2* | 6% | ||
FANCI | 1 | 3% | ||
NBN | 1 | 3% | ||
RAD51 | 1 | 3% | ||
SLX4 | 2* | 6% | ||
XRCC2 | 1 | 3% | ||
